Combination of biomarkers for the detection and evaluation of hepatitis fibrosis

Patent metadata

Field	Value
Publication number	US-9624541-B2
Application number	US-201213984702-A
Country	US
Kind code	B2
Filing date	Feb 9, 2012
Priority date	Feb 9, 2011
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:
SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.

First claim

The invention claimed is:

1. An in vitro method for determining the hepatic fibrosis score of a subject infected with one or more hepatitis viruses, characterized in that it comprises the following steps:
i) in a sample which has been obtained from said subject, measuring the levels to which the selected genes are translated, said selected genes the levels of translation of which are measured being the following combination of genes:
SPP1, A2M, IL8, CXCL10 and S100A4; and
ii) comparing the measurement values of each of said selected genes obtained for said subject with their values, or with the distribution of their values, in reference cohorts which have been pre-established as a function of their hepatic fibrosis score, in order to classify said subject into that of those reference cohorts to which it has the highest probability of belonging,
wherein the comparison in step ii) is made by combining said measurement values obtained in step i) into the linear Z function which is indicated for said combination of genes as:
Z= 0.241× A 2 M t +0.137× CXCL 10 t +0.001× IL 8 t +0.062× SPP 1 t +0.226× S 100 A 4 t ,

and, optionally, by comparison of the output value obtained thereby with the threshold δ of 2.905;
and wherein the classification of said subject into that of said reference cohorts to which it has the highest probability of belonging is made with:
a sensitivity (Se) of at least 67%; and/or with
a specificity (Sp) of at least 67%; and/or with
a negative predictive value (NPV) of at least 81%; and/or with
a positive predictive value (PPV) of at least 50%.

2. The method according to claim 1 , in which:
in addition to measuring the level at which the genes selected in step i) are translated, for said subject, the value of the following is measured, assayed or determined:
one or more clinical factor(s) selected from: sex, age at the date of sampling, body mass index, insulin sensitivity index, diabetes, alcohol consumption, degree of steatosis, mode of contamination or Metavir activity; and/or
one or more virological factor(s) selected from: viral genotype, duration of infection, viral load assayed for patient at treatment start date, or viral load assayed for patient at sampling date; and/or
one or more biological factor(s) other than the levels of transcription or translation of said selected genes, selected from: concentration of haptoglobin, concentration of apolipoprotein A1, total bilirubin content, concentration of gamma glutamyl transpeptidase, concentration of aspartate aminotransferase, concentration of alanine aminotransferase (ALT), platelet count, prothrombin count, quantity of cholesterol HDL, total cholesterol, concentration of ferritin, level of glycaemia, concentration of peptide C, insulin level, concentration of triglycerides, quantity of albumin, transferrin saturation, and concentration of alkaline phosphatase,
and in which
in step ii), the value(s) for this (these) factor(s) and the measurement values for the level of translation of said genes selected in step i) are compared with their values or with the distribution of their values in reference cohorts which have been pre-established as a function of their hepatic fibrosis score in order to classify said subject into that of those reference cohorts to which it has the highest probability of belonging.

3. The method according to claim 1 , in which said sample which has already been obtained from said subject is:
a biological sample which has already been taken from said subject, or
a sample comprising nucleic acids and/or proteins and/or polypeptides and/or peptides extracted or purified from said biological sample, or
a sample comprising cDNAs which are susceptible of having been obtained by reverse transcription of said nucleic acids,

said nucleic acids being RNAs,
said biological sample being
a biological tissue or cell sample which has already been removed or collected from the liver of said subject, or
a sample of biological fluid from said subject.

Assignees

• Watelet Bénédicte
• Asselah Tarik
• Bieche Ivan
• Batxelli Isabelle Catherine
• Jullian Nathalie
• Vidaud Michel
• Marcellin Patrick
• Laune Daniel
• Afshar Mohammad
• Mathieu Eve Laure
• Bio-Rad Innovations
• Ariana Pharmaceuticals
• Inst Nat Sante Rech Med
• Assist Publique—Hopitaux De Paris
• Centre Nat Rech Scient

Inventors

• Watelet Bénédicte
• Asselah Tarik
• Bieche Ivan
• Batxelli Isabelle Catherine
• Jullian Nathalie
• Vidaud Michel
• Marcellin Patrick
• Laune Daniel
• Afshar Mohammad
• Mathieu Eve Laure

Classifications

• G01N2800/7052

  Fibrosis · CPC title

• G01N33/576

  for hepatitis · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q1/6876 Primary

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title